Big caps bounce back for biopharma
Months of share price declines made 2022 a year to forget for many, but large-caps staged a big recovery in the fourth quarter.
Precision pays off for Prometheus
Strong mid-stage data defy doubts following rival Pfizer’s spin off.
Pfizer hands another asset to Roivant
Does yesterday’s deal with Roivant mean the pharma giant is cooling on TL1A targeting? And what about Prometheus?
Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Big pharma’s key fourth-quarter data
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
Prometheus takes on Pfizer in inflammatory bowel diseases
It is make or break time for the smaller group’s TL1A inhibitor PRA023.